AtriCure (NASDAQ:ATRC) and SNDL (NASDAQ:SNDL) Head-To-Head Contrast

AtriCure (NASDAQ:ATRC) and SNDL (NASDAQ:SNDL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations and price targets for AtriCure and SNDL, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	1	3	6	1	2.64
SNDL	1	0	1	0	2.00

AtriCure currently has a consensus price target of $48.43, indicating a potential upside of 67.63%. SNDL has a consensus price target of $5.00, indicating a potential upside of 281.68%. Given SNDL’s higher possible upside, analysts clearly believe SNDL is more favorable than AtriCure.

Valuation and Earnings

This table compares AtriCure and SNDL”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$534.53 million	2.69	-$11.45 million	($0.24)	-120.38
SNDL	$677.32 million	0.50	-$11.29 million	($0.04)	-32.75

SNDL has higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than SNDL, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

AtriCure has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Comparatively, SNDL has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500.

Institutional and Insider Ownership

99.1% of AtriCure shares are held by institutional investors. 3.5% of AtriCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares AtriCure and SNDL’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AtriCure	-2.14%	-1.15%	-0.88%
SNDL	-1.64%	-1.42%	-1.18%

Summary

AtriCure beats SNDL on 9 of the 15 factors compared between the two stocks.

About AtriCure

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

About SNDL

SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.